(Stroke. 1995;26:961-963.)
© 1995 American Heart Association, Inc.
Articles |
From the University Department of Neurology, Utrecht (J.E.C.B., G.J.E.R., A.A., J. van G.), and the University Department of Neurology, Academic Medical Centre, Amsterdam (M.L.), Netherlands.
Correspondence to Jacoline E.C. Bromberg, MD, University Department of Neurology, PO Box 85500, 3508 GA Utrecht, Netherlands.
| Abstract |
|---|
|
|
|---|
Methods We studied the outcome of familial SAH in a prospective, hospital-based series of patients with at least one first-degree relative with SAH and compared it with the outcome in a prospectively collected hospital series of patients selected for the absence of SAH in first- and second-degree relatives. Outcome was graded in three categories: independence, dependence, or death. Poor outcome was defined as death or dependence.
Results Of 29 patients with familial SAH, 52% had a poor outcome, whereas only 37% of 125 patients with sporadic SAH had a poor outcome. The crude relative risk for poor outcome in familial SAH was 1.4 (95% confidence interval [CI], 0.9 to 2.1; P=.14); the odds ratio adjusted for age and sex was 2.5 (95% CI, 1.0 to 6.0; P=.04). This risk is probably an underestimation due to our strict patient selection criteria.
Conclusions Patients with familial SAH have a greater risk of poor outcome than patients with sporadic SAH. This adds to the factors in favor of screening unaffected first-degree relatives of patients with familial SAH.
Key Words: aneurysm hereditary diseases outcome subarachnoid hemorrhage
| Introduction |
|---|
|
|
|---|
To assess the outcome of patients with familial SAH, we studied a series of patients with SAH who had at least one first-degree relative with SAH. We compared the outcomes in this series of familial SAH with those in a large, prospectively collected series of patients selected for the absence of SAH in first- and second-degree relatives.
| Subjects and Methods |
|---|
|
|
|---|
All histories and medical documents were classified independently and without information about relatives by two observers (J.E.C.B. and G.J.E.R.) according to criteria decided on in advance. When medical documents described clinical features suggestive of SAH in combination with blood in the basal cisterns on a CT scan, or xanthochromic CSF, or an aneurysm proved by angiography or autopsy, the relative was classified as having had SAH. Similarly, sudden, severe headache in combination with a normal neurological examination and hemorrhagic CSF followed by sudden deterioration consistent with rebleeding was also designated as SAH. Other descriptions of episodes suggestive of SAH were not included as SAH. The neurological condition on admission was graded according to the World Federation of Neurological Surgeons (WFNS) scale.8 Outcome at discharge from the hospital was graded according to the modified Glasgow Outcome Scale in three categories: independence, dependence, or death.9 In the outcome analysis we defined poor outcome as death or dependence. In the comparison of outcome for patients with familial and sporadic SAH, we used relative risks with matching 95% confidence intervals (CIs). Since baseline characteristics differed for the two groups, we used logistic regression analysis to calculate the odds ratio after adjustment for age and sex. We did not adjust for the condition at admission, since this variable was unknown in 8 of the 29 familial cases.
| Results |
|---|
|
|
|---|
|
Of the 29 familial cases, 52% had a poor outcome, whereas of the 125 patients with sporadic SAH, 37% had a poor outcome. The relative risk for poor outcome in a patient with familial SAH was 1.4 (95% CI, 0.9 to 2.1; P=.14); the odds ratio was 1.8 (95% CI, 0.8 to 4.2; P=.14). After adjustment for age and sex, the odds ratio was 2.5 (95% CI, 1.0 to 6.0; P=.04). Mortality alone in the patients with familial SAH was 38%, which is again higher than the 26% mortality in the series of sporadic SAH, with a relative risk of 1.5 (95% CI, 0.9 to 2.6).
| Discussion |
|---|
|
|
|---|
Our reference group is a prospective, hospital-based series of patients with sporadic SAH in whom extensive study revealed no first- or second-degree relatives with SAH or suspected SAH. Our series of familial SAH, in which the index patients were prospectively collected and hospital based, also includes relatives whose SAH had occurred previously but after 1975. Baseline characteristics of the two series were comparable: there was no difference in sex ratios or clinical condition at admission, but the mean age at which SAH occurred was significantly lower in familial patients. Although this lower mean age in familial patients would lead one to expect a better outcome in familial than in sporadic SAH, we found a worse outcome in familial SAH. In fact, after adjustment for age and sex the odds ratio for poor outcome in familial patients increased from 1.8 to 2.5 (95% CI, 1.0 to 6.0; P=.04).
Several other factors may have caused an underestimation of the proportion of patients with poor outcome in familial SAH. First, because the prognosis of SAH may have improved in the last decades,10 we excluded from our series of familial SAH 5 relatives who had their SAH before 1975. Four of these 5 had a poor outcome. Second, we excluded relatives with SAH who died before reaching a hospital, since our control series is hospital based. Third, our selection criteria exclude relatives with stroke in a poor clinical condition who died before ancillary investigations could be performed. Since at least some of these relatives had suffered an SAH, this is another source of bias toward a favorable outcome. All these factors influence the results in such a way that the difference in proportions of poor outcomes between familial and sporadic SAH is probably underestimated in our study.
We cannot explain the less favorable outcome in patients with familial SAH with certainty. It has been postulated that a hereditary defect in the arterial wall (for example, a connective tissue disorder) could be responsible for the development of intracranial aneurysms.4 11 12 13 One could hypothesize that this defect is more severe in familial cases, thus causing a more fragile vessel wall with larger aneurysms, which may entail a worse prognosis.14 However, since we included patients regardless of their clinical condition and therefore do not have complete data on the sizes of the aneurysms of our patients, we cannot test this explanation, and the similarity of the clinical condition at admission between familial and sporadic cases even challenges it. Although it is attractive to assume a structural factor in familial cases, collagen deficiency or other structural abnormalities of connective tissue have thus far not been demonstrated in familial cases of SAH.15
With the development of MR angiography, noninvasive screening for intracranial aneurysms now seems in the offing. The morbidity and mortality of elective surgery of unruptured aneurysms has become less than 3% in experienced hands,16 even for aneurysms of the posterior circulation.17 A recent decision analysis has indicated that catheter angiography to screen for familial intracranial aneurysms is justified in individuals between the ages of 40 and 60 years.18 The mortality and morbidity rates in this analysis were taken from older series,19 but happen to be similar to the rates we found in our series of familial SAH. The advice to screen for familial intracranial aneurysms between the ages of 40 and 60 years therefore still holds true. If, however, MR angiography is available, perhaps subjects at risk for familial SAH should be screened even in the age range of 20 to 70 years.20 This screening should be repeated at regular intervals, since new aneurysms can develop at any age.20 21 22
| Acknowledgments |
|---|
Received December 9, 1994; revision received March 13, 1995; accepted March 14, 1995.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Y.M. Ruigrok, G.J.E. Rinkel, A. Algra, T.W.M. Raaymakers, and J. van Gijn Characteristics of intracranial aneurysms in patients with familial subarachnoid hemorrhage Neurology, March 23, 2004; 62(6): 891 - 894. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J.H. Wermer, G. J.E. Rinkel, and J. van Gijn Repeated Screening for Intracranial Aneurysms in Familial Subarachnoid Hemorrhage Stroke, December 1, 2003; 34(12): 2788 - 2791. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yamada, M. Utsunomiya, K. Inoue, K. Nozaki, S. Miyamoto, N. Hashimoto, K. Takenaka, T. Yoshinaga, and A. Koizumi Absence of Linkage of Familial Intracranial Aneurysms to 7q11 in Highly Aggregated Japanese Families Stroke, April 1, 2003; 34(4): 892 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.J. Hademenos, M.J. Alberts, I. Awad, M. Mayberg, T. Shephard, A. Jagoda, R.E. Latchaw, H.W. Todd, K. Viste, R. Starke, et al. Advances in the genetics of cerebrovascular disease and stroke Neurology, April 24, 2001; 56(8): 997 - 1008. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wardlaw and P. M. White The detection and management of unruptured intracranial aneurysms Brain, February 1, 2000; 123(2): 205 - 221. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gaist, M. Væth, I. Tsiropoulos, K. Christensen, E. Corder, J. Olsen, and H. T. Sørensen Risk of subarachnoid haemorrhage in first degree relatives of patients with subarachnoid haemorrhage: follow up study based on national registries in Denmark BMJ, January 15, 2000; 320(7228): 141 - 145. [Abstract] [Full Text] |
||||
![]() |
A. Ronkainen, M. Niskanen, R. Piironen, and J. Hernesniemi Familial Subarachnoid Hemorrhage : Outcome Study Stroke, May 1, 1999; 30(5): 1099 - 1102. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Leblanc Familial Cerebral Aneurysms : A Bias for Women Stroke, June 1, 1996; 27(6): 1050 - 1054. [Abstract] [Full Text] |
||||
![]() |
J.E.C. Bromberg, G.J.E. Rinkel, A. Algra, P. Greebe, T. Beldman, and J. van Gijn Validation of Family History in Subarachnoid Hemorrhage Stroke, April 1, 1996; 27(4): 630 - 632. [Abstract] [Full Text] |
||||
![]() |
J. E C Bromberg, G. J E Rinkel, A. Algra, and J. Van Gijn Authors' reply BMJ, November 4, 1995; 311(7014): 1228a - 1228. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |